IMMX

Immix Biopharma Inc

IMMX, USA

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

https://www.immixbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IMMX
stock
IMMX

Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen Defense World

Read more →
IMMX
stock
IMMX

H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $12 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.95

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

27.31

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-91.78 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-37.78 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.43

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 11.26% of the total shares of Immix Biopharma Inc

1.

Bleichroeder LP

(2.9479%)

since

2025/06/30

2.

Vanguard Group Inc

(2.4226%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.6946%)

since

2025/07/31

4.

Geode Capital Management, LLC

(0.5588%)

since

2025/06/30

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4747%)

since

2025/07/31

6.

Morgan Stanley - Brokerage Accounts

(0.4332%)

since

2025/06/30

7.

Northern Trust Corp

(0.3256%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.27%)

since

2025/07/31

9.

Susquehanna International Group, LLP

(0.1763%)

since

2025/06/30

10.

State Street Corp

(0.149%)

since

2025/06/30

11.

BlackRock Inc

(0.1398%)

since

2025/06/30

12.

Timber Point Global Allocations Instl

(0.1387%)

since

2025/06/30

13.

iShares Micro-Cap ETF

(0.1272%)

since

2025/08/31

14.

Private Advisor Group, LLC

(0.1083%)

since

2025/06/30

15.

Tocqueville Asset Management L.P.

(0.1016%)

since

2025/06/30

16.

Velan Capital Investment Management LP

(0.0867%)

since

2025/06/30

17.

TRITONPOINT WEALTH LLC

(0.0851%)

since

2025/06/30

18.

Fidelity Total Market Index

(0.0769%)

since

2025/07/31

19.

Fidelity Series Total Market Index

(0.0701%)

since

2025/07/31

20.

NT Ext Equity Mkt Idx Fd - L

(0.0694%)

since

2025/06/30

21.

Northern Trust Extended Eq Market Idx

(0.0694%)

since

2025/06/30

22.

Spartan Extended Market Index Pool F

(0.0683%)

since

2025/07/31

23.

NT Ext Equity Mkt Idx Fd - NL

(0.0626%)

since

2025/06/30

24.

Virtu Financial LLC

(0.0619%)

since

2025/06/30

25.

SBI Securities Co Ltd

(0.0607%)

since

2025/06/30

26.

Northern Small Cap Core I

(0.0581%)

since

2025/06/30

27.

Commonwealth Equity Services Inc

(0.0556%)

since

2025/06/30

28.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0486%)

since

2025/06/30

29.

UBS Group AG

(0.0485%)

since

2025/06/30

30.

Fidelity Nasdaq Composite Index

(0.0476%)

since

2025/07/31

31.

The Colony Group LLC

(0.0413%)

since

2025/06/30

32.

Royal Bank of Canada

(0.0387%)

since

2025/06/30

33.

Spartan Total Market Index Pool G

(0.0294%)

since

2025/07/31

34.

NT Quality Small Cap Core

(0.0292%)

since

2025/06/30

35.

NT Quality SCC US Fund - L

(0.0292%)

since

2025/06/30

36.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0196%)

since

2025/06/30

37.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0165%)

since

2024/12/31

38.

Shaker Financial Discount Capture

(0.0156%)

since

2025/06/30

39.

Wells Fargo & Co

(0.0011%)

since

2025/06/30

40.

Bank of America Corp

(0.0005%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.15

Latest Release

Date

2025-09-30

EPS Actual

-0.24

EPS Estimate

-0.16

EPS Difference

-0.08

Surprise Percent

-50%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.